Literature DB >> 12078864

Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura.

Yasser A Wali1, Zakia Al Lamki, Wasifuddin Shah, Mathew Zacharia, Ahmed Hassan.   

Abstract

The effectiveness of pulsed high-dose oral dexamethasone therapy in children with refractory chronic idiopathic thrombocytopenic purpura (ITP) is evaluated. Thirteen children with severe chronic ITP were enrolled in the study from an outpatient pediatric hematology clinic (ages 2-14 years), 5 boys and 7 girls. They did not maintain a response to other forms of therapy (IVIg, Anti-D, conventional steroids, danazol) and one girl relapsed after splenectomy. Dexamethasone was administered orally at a dosage of 40 mg/M2/day (maximum 40 mg/day) for 4 consecutive days. The cycle was repeated once a month for 6 months. The immediate response to therapy was excellent as the mean platelet count at day 1 was 15 x 10(9)/L, while mean platelet count at day 4 was 158 x 10(9)/L. At the end of 6 cycles 3 patients maintained a platelet count of >150 x 10(9)/L and 4 patients showed partial response. At the end of the first year and second year (12 and 24 months after onset of treatment) 3 patients still had complete response, 3 patients had partial response, and 7 patients were failures. Six of the failures underwent splenectomy and one was shifted to dapsone, had no response, and refused splenectomy. Side effects were tolerable. They included bloating, nausea, vomiting, insomnia, anxiety, and depression, and transient glucosuria; however, they were not severe enough to discontinue the cycles. Mean duration of illness prior to start of dexamethasone was not significantly different in between responders and nonresponders. Dexamethasone given orally in high doses is an effective drug in achieving short-term platelet responses. Long-term remission is obtained in nearly half the patients with well-established chronic ITP. Its effectiveness in almost half the patients, minimal side effects, and low cost indicate that this treatment should be considered in patients with chronic ITP who do not tolerate the disease well before considering splenectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12078864     DOI: 10.1080/08880010290057345

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  8 in total

Review 1.  Immune thrombocytopenic purpura associated with rheumatoid arthritis: case report.

Authors:  Taro Horino; Atsushi Sasaoka; Toshihiro Takao; Takafumi Taguchi; Hiroshi Maruyama; Hiroyuki Ito; Shigeki Takemoto; Hirokuni Taguchi; Kozo Hashimoto
Journal:  Clin Rheumatol       Date:  2005-04-29       Impact factor: 2.980

Review 2.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

Review 3.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.

Authors:  Chengshan Guo; Xiaoxia Chu; Yan Shi; Weidong He; Lizhen Li; Lin Wang; Yingxue Wang; Jun Peng; Ming Hou
Journal:  J Clin Immunol       Date:  2007-07-06       Impact factor: 8.317

5.  Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura.

Authors:  Muhittin Celik; Ali Bulbul; Gönül Aydogan; Deniz Tugcu; Emrah Can; Sinan Uslu; Mesut Dursun
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 6.  Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.

Authors:  Fahad Aljebab; Imti Choonara; Sharon Conroy
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

7.  Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012.

Authors:  Sandra Regina Loggetto; Josefina Aparecida Pellegrini Braga; Mônica Pinheiro de Almeida Veríssimo; Wanderley Marques Bernardo; Leticia Medeiros; Andrea Thives de Carvalho Hoepers
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 8.  Management of immune thrombocytopenia: Korean experts recommendation in 2017.

Authors:  Jun Ho Jang; Ji Yoon Kim; Yeung-Chul Mun; Soo-Mee Bang; Yeon Jung Lim; Dong-Yeop Shin; Young Bae Choi; Ho-Young Yhim; Jong Wook Lee; Hoon Kook
Journal:  Blood Res       Date:  2017-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.